Fund Holdings — Kynam Capital Management, LP

Total Portfolio Value:
$1.34B
Total Bought:
$179.94M
Total Sold:
$73.79M
Net Transaction:
+$106.14M
Notable People:
Kynam Capital Management Gp,
Securities
▲▼
SharesValue
Q2 2025
▲▼
Q3 2025
▲▼
Change
▲▼
Q2 2025
▲▼
Q3 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Celldex Therapeutics, Inc.(CLDX)6,100,7296,100,7290$124.15M$157.83M11.75%+$33.68M
Syndax Pharmaceuticals, Inc.(SNDX)8,520,0008,520,0000$79.79M$131.08M9.76%+$51.29M
Vera Therapeutics, Inc.CL A(VERA)3,426,8874,027,800+600,913$80.74M$117.05M8.71%+$36.31M
Cogent Biosciences, Inc.(COGT)8,492,5577,886,172-606,385$60.98M$113.25M8.43%+$52.27M
Vaxcyte, Inc.(PCVX)3,071,5883,071,5880$99.86M$110.64M8.24%+$10.78M
Viridian Therapeutics, Inc.(VRDN)4,427,9274,427,9270$61.90M$95.55M7.11%+$33.65M
CG Oncology, Inc.(CGON)2,457,6672,005,205-452,462$63.90M$80.77M6.01%+$16.87M
BioCryst Pharmaceuticals, Inc.(BCRX)8,463,7429,390,270+926,528$75.84M$71.27M5.31%-$4.56M
Beam Therapeutics Inc.(BEAM)2,417,6472,517,647+100,000$41.12M$61.10M4.55%+$19.98M
Immunocore Holdings plcADS(IMCR)976,2671,009,267+33,000$30.64M$36.67M2.73%+$6.03M
MBX Biosciences, Inc.(MBX)02,000,000+2,000,000$0$35.00M2.61%+$35.00M
Engene Holdings Inc
COM
4,994,0904,994,0900$18.18M$34.11M2.54%+$15.93M
Wave Life Sciences, Inc.SHS(WVE)4,560,0534,560,0530$29.64M$33.38M2.49%+$3.74M
Tyra Biosciences, Inc.(TYRA)2,329,9982,329,9980$22.30M$32.60M2.43%+$10.30M
Travere Therapeutics, Inc.(TVTX)1,540,691949,727-590,964$22.80M$22.70M1.69%-$103.8K
Dynavax Technologies Corp2,145,3192,145,3190$21.28M$21.30M1.59%+$21.5K
Nurix Therapeutics, Inc.(NRIX)1,173,6052,168,605+995,000$13.37M$20.04M1.49%+$6.67M
United Therapeutics Corporation(UTHR)067,588+67,588$0$20.01M1.49%+$20.01M
Apellis Pharmaceuticals Inc
COM
0808,607+808,607$0$18.30M1.36%+$18.30M
Pharvaris N V
COM
0675,000+675,000$0$16.84M1.25%+$16.84M
Relay Therapeutics, Inc.(RLAY)2,887,0142,887,0140$9.99M$15.07M1.12%+$5.08M
Cullinan Therapeutics, Inc.(CGEM)2,095,9982,302,172+206,174$15.76M$13.65M1.02%-$2.11M
CytomX Therapeutics, Inc.(CTMX)2,154,4133,646,503+1,492,090$4.89M$11.63M0.87%+$6.74M
Amarin Corp PlcADR576,111576,1110$9.34M$9.44M0.70%+$92.2K
Burning Rock Biotech LimitedADS(BNR)994,883994,8830$3.14M$8.61M0.64%+$5.46M
Design Therapeutics, Inc.(DSGN)1,029,5791,029,5790$3.47M$7.75M0.58%+$4.28M
Kalvista Pharmaceuticals Inc0606,171+606,171$0$7.38M0.55%+$7.38M
Ironwood Pharmaceuticals, Inc.CL A(IRWD)5,466,8255,466,8250$3.92M$7.16M0.53%+$3.24M
Caribou Biosciences, Inc.(CRBU)3,067,7743,067,7740$3.87M$7.15M0.53%+$3.28M
UroGen Pharma Ltd.(URGN)656,573282,412-374,161$9.00M$6.94M0.52%-$2.06M
Geron Corporation(GERN)3,456,3183,456,3180$4.87M$4.74M0.35%-$138.3K
Sutro Biopharma, Inc.(STRO)5,088,0995,088,0990$3.63M$4.42M0.33%+$786.1K
Edgewise Therapeutics, Inc.(EWTX)253,979253,9790$3.33M$4.12M0.31%+$789.9K
Proqr Thrapeutics N VSHS EURO
SHS EURO
1,649,4621,649,4620$3.36M$3.51M0.26%+$148.5K
Climb Bio, Inc.(CLYM)1,028,3411,028,3410$1.28M$2.07M0.15%+$791.8K
Liquidia Corporation(LQDA)200,0470-200,047$2.49M$0—-$2.49M
Page 1 of 1
Kynam Capital Management, LP — 13F Holdings — Q3 2025 | TickerTrail